In the era of these recommendations, implementation of monitoring in the United Kingdom has not been previously reported. The aim of this population-based longitudinal study was to assess monitoring in patients on long-term amiodarone in the Tayside population (approximately 400 000) in United Kingdom between 1989 and 2011 and to determine the incidence of abnormal liver function tests and thyroid dysfunction in relation to total exposure of amiodarone, using the record-linkage Health Informatics Centre (HIC) dispensed prescription database in Tayside.
| METHODS
We conducted a retrospective observational population-based study of patients who had been prescribed amiodarone using record-linked administrative data. Using the unique Scottish patient identification Community Health Index (CHI) number, anonymized prescription data were linked utilizing the well-established Health Informatics Centre (HIC) record-linkage database in Tayside to demographic and laboratory results in order to obtain information regarding prescription and monitoring of each patient. 9 Indication for amiodarone was derived 
| Patient identification
Using the prescription-record-linkage database, all patients who were prescribed amiodarone over the 22 years were identified. Long term was defined as exposure ≥6 months (168 days) with regular prescriptions (time between two collected prescriptions ≤3 months).
| Amiodarone laboratory monitoring processes
were assessed for the following:
| Baseline evaluation (6 months before or 1 month of the first prescription)
Baseline testing was defined as blood tests 6 months before or 1 month after commencing amiodarone. The test with closest temporal proximity to the commencement of amiodarone was used to identify patients with abnormal liver or/and thyroid function. Patients with a baseline test three times the upper limit of normal (3×ULN) were excluded.
| Surveillance. Assessment of 6 monthly monitoring
Monitoring requirements were presumed to end once a patient stopped amiodarone medication. Frequency of testing was performed by analyzing the number of biochemical tests that were performed during the duration of amiodarone therapy. Tests performed <30 days apart were not included in analysis. A mean number of days between testing of ≤6 months were classed as adequate monitoring.
| Case Definitions of Laboratory Adverse Drug Reactions
The upper limit of normal (ULN) of alanine aminotransferase (ALT) was 40 U/L (Biochemistry Service, Ninewells Hospital, Dundee). 3×ULN
was regarded as an adverse drug reaction (ADR) for ALT.
Normal reference range for thyroid stimulating hormone (TSH) was defined between 0.4 and 4.5 mU/L. Hyperthyroidism was classified as TSH <0.4 mU/L and >10 mU/L as overt hypothyroidism.
10
TSH results from the 3-month period after starting amiodarone were excluded as TSH can transiently increase with amiodarone. 
| Statistical Analysis
Normally distributed logarithmic data were analyzed with one-way ANOVA (analysis of variance) and post hoc analysis (using Scheffe's method of multiple comparisons). Correlation of nonnormally distributed data was analyzed by Spearman's rank correlation coefficient, and nonparametric data were analyzed by chi-squared analysis.
Statistical analysis was performed using SPSS statistical software (version 18, SPSS; Chicago, USA). Table 1 . The study population was predominantly male (57%) and elderly (mean age 71 years) with 71% of patients treated with amiodarone 200 mg OD (Table 1) . 
| RESULTS

| Patient demographics
| Amiodarone prescribing
| Monitoring
| Liver dysfunction monitoring
Of the 1413 patients, 180 (13%) patients had no ALT testing. A total of 1233 (87%) had ALT tested at least once between 1 month of starting amiodarone to discontinuation, and 1046 (74%) patients had more than one test.
Adequate ALT monitoring occurred in 644 (46%), with 305 patients were tested for ALT yearly. The median number of days between testing was 153 days (~5 months) (range 32 days to 7.7 years).
| TSH monitoring
A total of 413 (29%) patients on thyroxine were excluded from the analysis, leaving 1000 (71%) patients not prescribed thyroxine: 172 (17%) never had thyroid function testing; 828 (83%) patients had TSH tested at least once, and 623 (62%) had more than one TSH test. Of the 1000 patients studied, 277 (28%) patients were adequately monitored at least 6 monthly, and 220 (22%) were monitored yearly. The median number of days between testing was 202 days (~7 months) (range 32 days-8.3 years).
| Combined ALT & TSH monitoring
A total of 562 (56%) patients had both ALT and TSH tested. Only 211 patients were adequately monitored (21% of 1000) every 6 months; 424 (42%) patients had both tests performed yearly.
The 211 patients monitored for both ALT and TSH as per guidelines were grouped into 5-year periods of when they started amiodarone (Table 2) . Monitoring for liver and thyroid toxicity has improved over 
| Pharmacological intervention for Thyroid abnormalities
A total of 140 (10%) patients were started on thyroxine at least (Table 3) , with a relative 9.5-and 17.5-fold increase in the incidence of hypothyroidism and hyperthyroidism, respectively. percentage of patients with an abnormal result is strongest in the first 4 years, with a 2.5-fold increase (6%-15%) in percentage of patients between the 1 and 4 year of amiodarone therapy.
| Total exposure to amiodarone and abnormal TFT
| DISCUSSION
The study provides an insight into the effect of amiodarone exposure and the attendant risks of ADRs. The results of this study show that a significant proportion of patients in the community are on amiodarone for considerably longer than 1 year and, importantly, the risk of LFT and TFT abnormalities increases with total exposure to amiodarone. 17 Other studies have demonstrated low monitoring rates, from 23% to 42%; however, their cohorts were of less than 100 patients. 18, 19 There are differences in the monitoring rates between Tayside and the USA, possibly related to differences in healthcare systems, but notably our study spans a 22-year era before and after guideline development and reports relatively contemporary data compared to previous studies.
The median total exposure of amiodarone in our study was ; however, we found that at 4 years of amiodarone at 200 mg OD, the risk of having an abnormal ALT test and TSH was increased 2.5-fold, to a prevalence of 11.6%.
Our study highlights that there is a need to monitor patients for toxicity even with relatively low doses. Indeed, 9.5% of patients in Tayside had at least one ALT result >3×ULN and 17% of patients had abnormal TSH results. Goldschlager et al. reported an incidence of 15%-30% for ALT >2×ULN 16 compared with 12.3% of patients in our study. One possible explanation for the difference is underreporting, as that 12% of patients in Tayside never had ALT tested. Similarly with TSH, where 17% of thyroxine naïve patients never had TSH tested.
A recent large cross-sectional study investigating the prevalence of prescribing and monitoring in primary care in the UK found that 42.2%
of patients did not have TFT monitoring within 6 months of their start date. The prevalence noted was higher than observed in our study;
however, reliability of the data (derived from the intraclass correlation coefficient) was low (0.47). as hepatitis, cirrhosis, or death are in short-term studies. [22] [23] [24] In addition, the risk of clinically significant hepatitis being missed remains.
Ten percent of our study population required thyroxine treatment, while 3% developed overt hyperthyroidism, similar to a 612-patient substudy of the SAFE-Trial, where 7% of study patients on amiodarone were prescribed levothyroxine with 5% of patients developed overt hyperthyroidism. 10 Nevertheless, the close monitoring of study subjects in the clinical trial program in contrast to the real-world setting where 17% of patients on amiodarone never had thyroid testing, resulting in cases thyroid dysfunction being possibly missed, suggests that there is a potential risk of underestimating thyroid dysfunction. Indeed, comparison with epidemiological data in Tayside 13 indicates that the incidence of hypothyroidism and hyperthyroidism during amiodarone treatment is increased by 9.5-and 17.5-fold, respectively, (Table 3) when compared to that of the background incidence. 12 The results also show that biochemical abnormalities indicative of hyperthyroidism while on amiodarone are more common than hypothyroidism, but clinically significant disease requiring pharmacological intervention is much lower.
Our results demonstrate a direct correlation between length of exposure to amiodarone and abnormal biochemical results. Previous studies have shown small correlations with duration of treatment and ADRs. 22, 24 More recently, a large 12-year study of 930 patients found that duration of treatment was the only independent predictor of adverse effect (OR 1.21 per year, P=.016). 25 A previous meta-analysis of adverse effects of low-dose amiodarone found the odds for hepatotoxicity was similar to that of the control group at 12 months. 2 Indeed, our data show that ALT abnormalities do not commonly develop in the first year of 200 mg daily amiodarone (4.7%), but importantly increases thereafter, with the number of patients with an abnormal ALT result increased 2.5-fold over the following 4-years' worth of 200 mg OD equivalent dosing.
Previous studies have found that thyroid toxicity typically occurs in the first 24 months. 16 However, our study found that thyroid function abnormalities occurred later with the median number of days from starting amiodarone to biochemical hyperthyroidism and hypothyroidism being 560 days (90-3761 days) and 609 days (92-4586 days),
respectively. Yet, despite the small sample sizes in the increasing exposure years, our study shows that there is a continued increase in the incidence of thyroid toxicity in this reduced cohort.
| LIMITATIONS
Being a retrospective linkage study, there were several limitations including lack of access to clinical data to correlate biochemical abnormalities. This may have resulted in overestimating ADRs as we were unable to identify other potential causes. We were also not able to determine the incidence of other amiodarone ADRs or the clinicians' decision to continue or discontinue amiodarone, and reasons for poor monitoring. We included only incident thyroid disease by selecting patients diagnosed after 6 months on amiodarone; however, we were unable to exclude previous resolved thyroid disease. After 4-years' worth of 200 mg OD dosing exposure equivalent, the relationship with biochemical abnormalities was unpredictable, possibly because of the small number of patients with prolonged exposure, resulting in fewer person years follow-up, which may also limit the comparison of incidence of thyroid abnormalities using the TEARS data.
| CONCLUSION
This retrospective study, which we believe to be the largest and longest follow-up study of amiodarone monitoring in a public healthcare service, has identified the increasing risk of developing ADRs with continued exposure to amiodarone. Although the majority of these will be of minimal significance, there remains a risk of clinical significant ADRs being missed through poor adherence to monitoring guidance, highlighting the need for improved surveillance. While monitoring practice has improved in accordance with current guidelines, there is still a shortfall in achieving safe standards, which is of particular concern, as amiodarone remains the most widely prescribed antiarrhythmic drug worldwide. Consideration of strategies to improve monitoring in patients who are prescribed amiodarone such as the introduction of a shared care protocol between primary and secondary care or computerized prescribing prompts, which have shown to be effective, 26 may reduce amiodarone toxicity through education and active intervention.
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